David Doležil

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

Stewart J. Tepper, Messoud Ashina, Uwe Reuter et al. · The Lancet Neurology · 2017 · 735 citations

Medicine, Neurology, Pharmacology +9

A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention

Messoud Ashina, David Doležil, Jo Bonner et al. · Cephalalgia · 2020 · 171 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

Messoud Ashina, Stewart J. Tepper, Jan Lewis Brandes et al. · Cephalalgia · 2018 · 157 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

Stewart J. Tepper, Messoud Ashina, Uwe Reuter et al. · Cephalalgia · 2020 · 106 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions

Messoud Ashina, David Kudrow, Uwe Reuter et al. · Cephalalgia · 2019 · 72 citations

Pharmacy, Pharmacology, Pharmacotherapy +17